BeyondSpring receives US patent covering methods of treating brain tumor by administering Plinabulin
BeyondSpring, a global biopharmaceutical company focused on the development of innovative cancer therapies, announced that the United States Patent Office has granted the company a new patent, US Patent No. 10,357,491 B2, for methods of treating a brain tumor by administering Plinabulin.
The patent, which expires in 2036, covers methods for Plinabulin’s use in the treatment of brain tumors, including metastatic brain tumor, with no approved chemotherapy on the market, and glioblastoma multiforme (GBM), the most common adult brain tumor. Both are known for their lethality and lack of response to treatment using the current standard of care. Dr. Lan Huang, BeyondSpring co-founder and CEO, is the inventor of the new patent.
Only surgery and radiation, but no chemotherapy had ever been granted in metastatic brain tumor, with survival at around 4 to 6 months. Without the current advancement in primary tumor treatment, more patients would develop metastatic brain tumor with grim outcome. In recent years, there have been no substantial improvements in treatment options, and minimal improvements in the survival prospects for patients with GBM. The average life expectancy for GBM after symptoms onset is approximately 6 to 12 months.